Tips

十一月美迪西將主辦2 場線上直播，同時參與5 場海內外行業會議，期待與各位業內同仁交流分享藥物研發新趨勢。

15^th World ADC San Diego 2024

Antibody-drug conjugates are an important class of therapeutics for the treatment of cancer. ADCs are coming of age with a remarkable surge in recent times, that has marked a turning point in their development. 15^th World ADC San Diego 2024 is only one week to go!

We are excited to invite you to visit us at Medicilon Booth #512. Our Science and Business teams are looking forward to meeting you.

SITC 2024

Ready to Meet Medicilon at SITC's 39^th Annual Meeting & Pre-Conference Programs (SITC2024)? 

We are happy to meet you in person to discuss how our services and capabilities can support your research and expedite your drug discovery and development activities. Cellular immunotherapy has developed by leaps and bounds in recent years, providing a cure for many difficult-to-treat cancers. Medicilon has built a one-stop service platform for the preclinical R&D of cellular immunotherapies, covering a variety of immunotherapy methods including CAR-T, TCR-T and CAR-NK. Using a wealth of animal models and a variety of advanced analysis techniques, comprehensively considering the characteristics of different research projects, Medicilon has completed numerous pre-clinical projects for clients worldwide.

首屆創新藥研發和多維度治療前沿峰會

2024年11月9-10日，由四川大學華西醫院、中國細胞生物學學會主辦，中國免疫學會、四川大學華西醫院生物治療全國重點實驗室、四川省國際醫學交流促進會、四川大學華西醫院免疫炎癥研究院聯合主辦，蘇州盛杰、GenEros Bio Pharma、健橋海承辦的“首屆創新藥研發和多維度治療前沿峰會暨JAK-STAT信號通路發現30周年慶典”將在成都舉辦。

美迪西創始人&CEO陳春麟博士將分享“Efficacy and Preclinical Research on JAK3 Inhibitor JANEX-1 for Treatment of Allergic Reaction and Asthma”！

美迪西團隊將在1號展位全程設展！

第十七屆百世化學制藥國際大會暨展覽會

2024年11月13-14日，由百世傳媒主辦，廣東醫谷、廣東省藥學會制藥工程專業委員會、廣東省生物醫藥創新技術協會、全球健康藥物研發中心、聊城大學生物制藥研究院等聯合主辦的“CIS-Asia 2024 第十七屆百世化學制藥國際大會暨展覽會”將在廣州舉辦。

美迪西化學部研發副總裁李志剛博士將分享“以靶向EGFR的PROTAC藥物研發為例的X-TAC研發思考”！

美迪西團隊將在25號展位全程設展！

ACT 2024

American College of Toxicology (ACT) 2024 kicks off on November 17 2024 at JW Marriott Austin, Austin, Texas. Maybe we can work together and Medicilon can be a great partner! Come and chat with our American team at booth #117! Medicilon offers comprehensive toxicology study services designed to assess the safety profile and potential risks of pharmaceutical compounds. Our expert team collaborates closely with clients to tailor studies according to regulatory requirements and project-specific needs. Our state-of-the-art facilities, advanced platform, experienced scientists, and commitment to quality ensure that clients receive high quality, reliable, and regulatory-compliant GLP toxicology data to support the development of safe and effective pharmaceutical products. Medicilon has been at the forefront of pharmaceutical R&D for over 20 years. We have supported more than 2,000 global clients and have contributed to the IND approval of more than 490 drugs.

marketing@medicilon.com.cn
媒體與會務請聯系
美迪西市場部微信或郵箱